Dateline City:
BOSTON
Priority Review Designation for MK-3475 BLA for Proposed Indication of Unresectable or Metastatic Melanoma in Patients Who Have Been Previously Treated with Ipilimumab
Advancing New Phase 3 Studies with MK-3475 in Adjuvant Melanoma, Previously-Untreated Non-Small Cell Lung Cancer, Advanced Head & Neck and Bladder Cancers
Data from Studies in Three Different Cancer Types to be presented at 2014 ASCO Annual Meeting
Initiating Phase 1 Study with Investigational Anti-GITR Antibody (MK-4166)
BOSTON--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada,
today announced that the U.S. Food and Drug Administration (FDA) has
accepted for review the Biologics License Application (BLA) for MK-3475,
Mercks investigational anti-PD-1 antibody, for the treatment of
unresectable or metastatic melanoma in patients who have been previously
treated with ipilimumab.
Language:
English
Contact:
MerckMedia:Ian McConnell, 973-901-5722Claire Mulhearn, 908-423-7425orInvestors:Carol Ferguson, 908-423-4465Justin Holko, 908-423-5088
Ticker Slug:
Ticker: MRK Exchange: NYSE
read more